Literature DB >> 22515595

Oxidized low-density lipoprotein and lipoprotein(a) levels in chronic kidney disease patients under hemodialysis: influence of adiponectin and of a polymorphism in the apolipoprotein(a) gene.

Sandra Ribeiro1, Maria do Sameiro Faria, Gil Silva, Henrique Nascimento, Petronila Rocha-Pereira, Vasco Miranda, Emília Vieira, Rosário Santos, Denisa Mendonça, Alexandre Quintanilha, Elísio Costa, Luís Belo, Alice Santos-Silva.   

Abstract

Chronic kidney disease (CKD) has been associated with an abnormal lipid profile. Our aim was to study the interplay between oxidized low-density lipoprotein (ox-LDL), adiponectin, and blood lipids and lipoproteins in Portuguese patients with CKD under hemodialysis (HD); the influence of the pentanucleotide repeat polymorphism in the apolipoprotein(a) (apo [a]) gene upon lipoprotein(a) (Lp[a]) levels in these patients. We studied 187 HD patients and 25 healthy individuals. ox-LDL and adiponectin were measured using enzyme-linked immunoassays. Apo(a) genotyping was performed by polymerase chain reaction, followed by electrophoresis in polyacrylamide gel. Compared with controls, patients presented with significantly higher levels of adiponectin, Lp(a), and ox-LDL/low-density lipoprotein cholesterol (LDLc) ratio; significantly lower levels of total cholesterol (TC), LDLc, apo A-I, apo B, ox-LDL, and TC/high-density lipoprotein cholesterol (HDLc) ratio were also observed. Similar changes were observed for patients with or without statin therapy, as compared with controls, except for Lp(a). Multiple linear regression analysis showed that body mass index, HDLc, time on HD, and triglycerides (TG) were independent determinants of adiponectin levels, and that apo B, TG and LDLc were independent determinants of ox-LDL concentration. Concerning the apo(a) genotype, the homozygous (TTTTA)8/8 repeats was the most prevalent (50.8%). A raised proportion of LDL particles that are oxidized was observed. Adiponectin almost doubled its values in patients and seems to be an important determinant in HDLc and TG levels, improving the lipid profile in these patients. Apo(a) alleles with a lower number of repetitions are more frequent in patients with higher Lp(a).
© 2012 The Authors. Hemodialysis International © 2012 International Society for Hemodialysis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22515595     DOI: 10.1111/j.1542-4758.2012.00687.x

Source DB:  PubMed          Journal:  Hemodial Int        ISSN: 1492-7535            Impact factor:   1.812


  8 in total

Review 1.  The effect of chronic kidney disease on lipid metabolism.

Authors:  Neris Dincer; Tuncay Dagel; Baris Afsar; Adrian Covic; Alberto Ortiz; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2018-12-05       Impact factor: 2.370

Review 2.  Cardiovascular Risk Stratification in Diabetic Retinopathy via Atherosclerotic Pathway in COVID-19/Non-COVID-19 Frameworks Using Artificial Intelligence Paradigm: A Narrative Review.

Authors:  Smiksha Munjral; Mahesh Maindarkar; Puneet Ahluwalia; Anudeep Puvvula; Ankush Jamthikar; Tanay Jujaray; Neha Suri; Sudip Paul; Rajesh Pathak; Luca Saba; Renoh Johnson Chalakkal; Suneet Gupta; Gavino Faa; Inder M Singh; Paramjit S Chadha; Monika Turk; Amer M Johri; Narendra N Khanna; Klaudija Viskovic; Sophie Mavrogeni; John R Laird; Gyan Pareek; Martin Miner; David W Sobel; Antonella Balestrieri; Petros P Sfikakis; George Tsoulfas; Athanasios Protogerou; Durga Prasanna Misra; Vikas Agarwal; George D Kitas; Raghu Kolluri; Jagjit Teji; Mustafa Al-Maini; Surinder K Dhanjil; Meyypan Sockalingam; Ajit Saxena; Aditya Sharma; Vijay Rathore; Mostafa Fatemi; Azra Alizad; Vijay Viswanathan; Padukode R Krishnan; Tomaz Omerzu; Subbaram Naidu; Andrew Nicolaides; Mostafa M Fouda; Jasjit S Suri
Journal:  Diagnostics (Basel)       Date:  2022-05-14

3.  Activation of platelet-activating factor receptor exacerbates renal inflammation and promotes fibrosis.

Authors:  Matheus Correa-Costa; Vinicius Andrade-Oliveira; Tarcio T Braga; Angela Castoldi; Cristhiane F Aguiar; Clarice S T Origassa; Andrea C D Rodas; Meire I Hiyane; Denise M A C Malheiros; Francisco J O Rios; Sonia Jancar; Niels O S Câmara
Journal:  Lab Invest       Date:  2014-02-03       Impact factor: 5.662

4.  Association of Plasma Adiponectin and Oxidized Low-Density Lipoprotein with Carotid Intima-Media Thickness in Diabetic Nephropathy.

Authors:  Anna Tavridou; Anastasia Georgoulidou; Athanasios Roumeliotis; Stefanos Roumeliotis; Efstathia Giannakopoulou; Nikolaos Papanas; Ploumis Passadakis; Vangelis G Manolopoulos; Vassilis Vargemezis
Journal:  J Diabetes Res       Date:  2015-05-12       Impact factor: 4.011

Review 5.  Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.

Authors:  Nans Florens; Catherine Calzada; Egor Lyasko; Laurent Juillard; Christophe O Soulage
Journal:  Toxins (Basel)       Date:  2016-12-16       Impact factor: 4.546

Review 6.  Adiponectin and chronic kidney disease; a review on recent findings.

Authors:  Maryam Heidari; Parto Nasri; Hamid Nasri
Journal:  J Nephropharmacol       Date:  2015-07-27

7.  Gene Cascade Shift and Pathway Enrichment in Rat Kidney Induced by Acarbose Through Comparative Analysis.

Authors:  Chun-Yue Weng; Mo-Han Zhu; Ke-Lei Dai; Zhe-Yan Mi; Yuan-Shan Wang; Zhi-Qiang Liu; Yu-Guo Zheng
Journal:  Front Bioeng Biotechnol       Date:  2021-05-21

Review 8.  Cholesterol Disturbances and the Role of Proper Nutrition in CKD Patients.

Authors:  Anna Gluba-Brzozka; Beata Franczyk; Jacek Rysz
Journal:  Nutrients       Date:  2019-11-18       Impact factor: 5.717

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.